We evaluated the impact of triple antiplatelet therapy on platelet reactivity, reducing cardiovascular events and the safety in obese patients undergoing coronary stenting. Obese patients (n = 428) undergoing coronary stenting were randomly assigned to 2 groups: standard dual group (clopidogrel plus aspirin, n = 215) and triple group (n = 213); adjunctive cilostazol was added to the dual group treatment. Platelet reactivity was assessed at baseline and at 1-year follow-up by conventional aggregometry. Major adverse cardiovascular events, stent thrombosis, target lesion revascularization (TLR), target vessel revascularization, and bleeding events were analyzed after 1-year follow-up. At 1-year follow-up after stenting, major adverse cardiac events including death, myocardial infarction, and ischemic-driven TLR were lower in the triple group than the dual group. Major bleeding was similar in both the groups. In obese patients undergoing percutaneous coronary intervention, triple antiplatelet therapy was superior to dual antiplatelet therapy in decreasing thrombotic events in 12-month cardiac events, mainly driven by a decrease in the incidence of clopidogrel resistance.
AngiolilloDJFernandez-OrtizABernardoE. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res. 2005;115(1-2):101–108.
2.
MatetzkySShenkmanBGuettaV. Clopidogrel resistance is a associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109(25):3171–3175.
3.
MobleyJEBreseeSJWorthamDCCraftRMSniderCCCarrollRC. Frequency of nonresponse antiplatelet therapy activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol. 2004;93(4):456–458.
4.
MullerIBestaFSchultzCMassbergSSchonigAGawazM. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Res. 2003;89(5):783–787.
5.
WangZJZhouYJLiuYY. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent. Thromb Res. 2009;124(1):46–51.
6.
GurbelPABlidenKPHiattBLO'ConnorCM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107(23):2908–2913.
7.
GurbelPASamaraWMBlidenKP. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Platelets. 2004;15(2):95–99.
8.
AlmsherqiZAMcLachlanCSMossopPDengY. Optimal antiplatelet treatment for precutaneous coronary intervention: clopidogrel vs. ticlopidine. Int J Cardiol. 2007;114(1):101–102.
9.
WangZJZhouYJLiuYY. Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents. Heart. 2009;95(19):1587–1592.
10.
AngiolilloDJFernández-OrtizABernardoE. Platelet aggregation according to BMI in patients undergoing coronary stenting: should clopidogrel loading dose be weight adjusted?J Invasive Cardiol. 2004;16(4):169–174.
11.
BuonamiciPMarcucciRMiglioriniA. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007;49(24):2312–2317.
12.
FeherGKoltaiKAlkonyiB. Clopidogrel resistance: role of body mass and concomitant medications. Int J Cardiol. 2007;120(2):188–192.
13.
TamminenMLassilaRWesterbackaJ. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord. 2003;27(8):907–911.
14.
Ferro-LuzziAGarzaCHaasJ. Physical status: the use interpretation of anthropometry: report of a WHO Expert Committee. WHO Tech Rep Ser. 1995;854(1):1–452.
15.
WiviottSDTrenkDFrelingerAL. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation. 2007;116(25):2923–2932.
16.
GurbelPASerebruanyVLShustovAR. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. J Am Coll Cardiol. 1998;31(7):1466–1473.
17.
RuggeriZM. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol. 1994;31(3):29–39.
18.
GurbelPABlidenKPHayesKMYohoJAHerzogWRTantryUS. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol. 2005;45(9):1392–1396.
19.
LeeSWParkSWHongMK. Triple versus dual antiplatelet therapy after coronary stenting. J Am Coll Cardiol. 2005;46(10):1833–1837.
20.
CuissetTFrereCQuiliciJ. High post-treatment platelet reactivity identified low responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost. 2006;4(3):542–549.
21.
MarcucciRGoriAMPanicciaR. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay. Circulation. 2009;119(2):237–242.
22.
BuonamiciPMarcucciRMiglioriniA. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007;49(24):2312–2321.
23.
GurbelPABlidenKPGuyerK. Platelet reactivity in patients and recurrent events post-stenting: results of the prepare poststenting study. J Am Coll Cardiol. 2005;46(10):1820–1826.
24.
AjzenbergNAubryPHuisseMG. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. J Am Coll Cardiol. 2005;45(11):1753–1756.
25.
GotoS. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl. 2005;6(4):3–11.
26.
KimuraYTaniTKanbeTWatanabeK. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung. 1985;35(7A):1144–1149.
27.
ChKYRhaSWLiYJ. Triple versus dual antiplatelet therapy in patients with acute st-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation. 2009;119(25):3207–3214.
28.
LeeSWChunKJParkSW. Comparison of triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug–eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials). Am J Cardiol. 2010;105(2):168–173.
